Journal
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
Volume 10, Issue 2, Pages 413-424Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13346-019-00682-7
Keywords
Paclitaxel; Colon; Cancer; Fibroin; Nanoparticles; EDC; Crosslinked
Funding
- Thailand Research Fund (TRF) under the Royal Golden Jubilee (RGJ) Ph.D. Grant [PHD/0234/2560 RGJ]
- Naresuan University [R2561B009]
Ask authors/readers for more resources
Colon cancer is one of the most life-threatening cancers with high incidence and mortality rates. Current first-line treatments are ineffective and possess many unwanted effects. The off-label use of paclitaxel encapsulated in nanoparticles proves an innovative approach. In this study, we reported novel paclitaxel loaded EDC-crosslinked fibroin nanoparticles (PTX-FNPs) for anticancer purpose. The particles were formulated using desolvation method and the physicochemical properties were controlled favorably, including the particle size (300-500 nm), zeta potential (- 15 to + 30 mV), drug entrapment efficiency (75-100%), crystallinity, drug solubility (1- to 10-fold increase), dissolution profiles, stability (> 24 h in intravenous diluent and > 6 months storage at 4 degrees C). In in vitro study, all formulations showed no toxicity on the red blood cells, whereas retained the paclitaxel cytotoxicity on MCF-7 breast cancer and Caco-2 colon cancer cells. Interestingly, PTX-FNPs can be uptaken rapidly by the Caco-2 cells, consequently increased paclitaxel potency up to 10-fold compared to the free drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available